europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

EuropaBio Response to the Public Consultation on Blood, tissues and cells for medical treatments & therapies

16/04/2021
FEEDBACK

EuropaBio Response to the Public Consultation on Blood, tissues and cells for medical treatments & therapies ’

Brussels, 16 April 2021 -EuropaBio sent the response to the European Commission’s public consultation on the use of blood, tissues and cells for medical treatments and therapies (hereafter, BTC). Representing developers of cell-based and plasma-derived medicinal products, EuropaBio advocates the European Union’s uptake of transformative advanced therapies which hold a great potential for the health and wellbeing of patients and the sustainability of healthcare systems. EuropaBio believes, that while the Commission consultations cover the full scope of the BTC legislation, there is need for bespoke policies for different categories of products.

Cell-based medicinal products
A revision of the BTC legislation should address the existing inconsistencies within the regulatory framework and set clear boundaries between the legislation for human medicinal products and the BTC legislation. For example, some advanced therapy medical products (hereafter, ATMPs) are at the borderline between the two frameworks which creates administrative burden for many sector’s developers. The BTC legislation should apply up to the point of procurement and testing of the drug substance. Once the drug product enters manufacturing, the available ATMP guidance applies. Moreover, the BTC legislation should clarify the minimum requirements for donation, procurement and testing in cases where human tissues and cells are used as a starting material for ATMPs. The lack of harmonisation at national level should also be addressed. Existing practice shows that very often multiple responsible authorities are assigned for both facility licensing and inspections procedures. More harmonisation is needed also on international level. In addition, the new framework should be adaptive to new scientific and technical developments in the field of ATMPs and any new EU-level requirements should be justified.

Plasma-derived medicinal products
Therapy developers need to collect sufficient plasma to manufacture plasma-derived therapies to meet the needs of European patients and mitigate the possible supply disruptions which increases a dependency from the third countries. We, therefore, call on the EU to take a leadership role in supporting Member States to increase their plasma collection. We need a framework that differentiates between whole blood for transfusion and plasma for fractionation and develops bespoke rules and allows the coexistence of public sector and private sector plasma collection centres as well as compensation of donors for the expenses and inconvenience related to the donation. A constant development of science and innovation requires consistent updates of testing requirements. EuropaBio suggests creating a clear mechanism to facilitate this process. The relevant expert bodies such as the European Centre for Disease Prevention (ECDC) or the European Directorate for the Quality of Medicines (EDQM) or any other EU body could help to ensure that pace with scientific innovation can be kept while avoiding the potential delays of updates via legislation.

Download the full PRESS RELEASE below.

EuropaBio Response to the Public Consultation on Blood, tissues and cells for medical treatments & therapies ’


Download
BTC-consultation-fo-website_140421_finalDownload

Share
Alexandra Simionca
Alexandra Simionca

Related posts

23/03/2023

Unlocking the Potential of Biotechnology Innovation for Patients


Read more
16/03/2023

Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future


Read more
07/03/2023

Disc Medicine joins EuropaBio: life-changing medicines for patients with hematologic disorders


Read more
06/03/2023

Can the Pharmaceutical Strategy Deliver for Europe?


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies